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Abstract. Nasal administration of inﬂuenza vaccine has the potential to facilitate inﬂuenza control and
prevention. However, when administered intranasally (i.n.), commercially available inactivated vaccines
only generate systemic and mucosal immune responses if strong adjuvants are used, which are often
associated with safety problems. We describe the successful use of a safe adjuvant Gram-positive
enhancer matrix (GEM) particles derived from the food-grade bacterium Lactococcus lactis for i.n.
vaccination with subunit inﬂuenza vaccine in mice. It is shown that simple admixing of the vaccine with
the GEM particles results in a strongly enhanced immune response. Already after one booster, the i.n.
delivered GEM subunit vaccine resulted in hemagglutination inhibition titers in serum at a level equal to
the conventional intramuscular (i.m.) route. Moreover, i.n. immunization with GEM subunit vaccine
elicited superior mucosal and Th1 skewed immune responses compared to those induced by i.m. and i.n.
administered subunit vaccine alone. In conclusion, GEM particles act as a potent adjuvant for i.n.
inﬂuenza immunization.
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INTRODUCTION
Seasonal inﬂuenza is still one of the major causes for
mortality and morbidity worldwide (1). Annual vaccinations
are the most effective strategy to prevent and control
inﬂuenza infections (2,3). Most of the available inﬂuenza
vaccines are administered via the intramuscular (i.m.) or
subcutaneous route. These parenteral vaccines induce good
systemic immune response but no mucosal immune response
(3–5), which limits their protective efﬁcacy. In contrast,
intranasal (i.n.) vaccines may induce both systemic and
mucosal immune responses (6–9). In addition, i.n. delivery
of the vaccine does not require trained health care personnel
for the administration of vaccine, is suitable for people with
needle phobia, and circumvents the problem of needlestick
injuries (10).
A mucosal immune response is necessary for the protec-
tion of the upper respiratory tract, i.e., the port of entry for
inﬂuenza virus (6,11). The protection of the upper respiratory
tract is mainly provided by sIgA (3,6,12). Moreover, sIgA is
knowntoinducecross-protection againstvariantviruseswithin
the same subtype and also increase the protection during
epidemics of heterologous viruses (6,13–18). Furthermore, it is
reportedthatthemucosalimmunesystemdevelopsearlyinlife
and is not affected by aging (19,20). Therefore, a concomitant
advantage of i.n. inﬂuenza immunization is that it can
potentially provide effective immunity in all age groups and
can be used for mass vaccination.
Currently, live attenuated inﬂuenza virus vaccines
(LAIV) are marketed for i.n. administration. LAIV vaccines
have shown to induce both systemic and mucosal immune
responses. However, LAIV vaccine is licensed by the Food
and Drug Administration only for persons aged 2–49 years
but not for use in high-risk populations (elderly, children, and
chronically ill patients) (21,22). However, most of the
marketed inﬂuenza vaccines are inactivated vaccines which
can be administered safely via i.n. route to the whole
population. A disadvantage of these vaccines is that they
have shown to be poorly immunogenic when administered via
this route (4,13).
To increase the immunogenicity, inactivated inﬂuenza
vaccines require adjuvants to potentiate the immune response
when administered via the i.n. route. Several adjuvants are
currently under development for i.n. immunizations like
virus-like particles (23), immunostimulating complexes
(ISCOMS) (23), lipids, nucleic acids (24), and bacterial
components (25,26). However, the development of many of
these adjuvants systems is hampered by safety and regulatory
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heat liable toxin of Escherichia coli (LT) have shown severe
side effects in humans (28). Therefore, an adjuvant for i.n.
inactivated inﬂuenza vaccine that is potent and safe for
human use is still lacking.
The novel adjuvant Gram-positive enhancer matrix
(GEM) particles are produced from the food-grade bacterium
Lactococcus lactis (29). L. lactis is a nonpathogenic, non-
colonizing Gram-positive bacterium. Moreover, L. lactis is
approvedfor human use byregulatory agencies andconsidered
as a generally recognized as safe (GRAS) organism. The GEM
particles are produced by heating the L. lactis in acid, followed
by washing with phosphate buffer (30). The resulting particles
are nonliving, deprived of intact surface proteins and intra-
cellular content. The thick peptidoglycan cell wall, however,
remains intact and provides the structural rigidity to constitute
the bacterial-shaped peptidoglycan spheres of about 1 μmi n
size, referred to as GEM particles. The GEM particles have
been studied for mucosal vaccination of malarial parasite
antigen and pneumococcal antigens (31–33). These studies
demonstrated that antigens displayed on GEM particles
induced higher immune response than antigen alone. Since
GEM particles are a promising adjuvant for i.n. immunization,
theaimofthisstudywastoinvestigatetheuseofGEMparticles
as adjuvant for i.n. inﬂuenza vaccination.
In this study, we examined the immunogenicity in Balb/c
mice of i.n. administered inﬂuenza subunit vaccine mixed
with GEM particles as adjuvant. In earlier studies, the
antigens (pneumococcal and malarial) were covalently bound
to the GEM particles (29–33). In contrast, in the present
study, the particles were simply mixed with the antigens. The
immune response was compared to i.m. and i.n. administered
subunit inﬂuenza vaccine without the adjuvant.
MATERIALS AND METHODS
Inﬂuenza monovalent subunit vaccine of strain A/
Wisconsin (H3N2) was kindly provided by Solvay Pharma-
ceuticals (Weesp, The Netherlands). The concentration of
the hemagglutinin (HA) in the vaccine was determined using
the single radial immunodiffusion assay.
Gem Preparation
GEM particles were prepared as described earlier (29).
In brief, cells of an overnight culture of L. lactis strain
MG1363acmAΔ1 were harvested and washed once with
sterile distilled water. The cells were resuspended in 10%
trichloroacetic acid and placed in a hot water bath of 99°C for
30 min. The acid and heat treatment kills the bacteria and
generates the so-called GEM particles. After acid and heat
treatment, the GEM particles were pelleted and washed three
timesin phosphate buffered saline (PBS;Dulbecco’s phosphate
buffered saline without CaCl2 and MgCl2) and ﬁnally resus-
pendedin PBS andstored at −20°C. Oneunit of GEMparticles
was deﬁned as approximately 2.5×10
9 nonliving particles.
Immunization
Animal experiments were evaluated and approved by
the Committee for Animal Experimentation of the University
of Groningen, The Netherlands according to the guidelines
provided by Dutch Animal Protection Act. Balb/c mice (6–
8 weeks) purchased from Harlan, Zeist, The Netherlands
were used for all immunization experiments. The mice were
divided in three groups of eight each. All three groups of
animals were immunized with prime vaccination on day 0 and
two booster vaccinations on days 14 and 28 with 5 μg of HA.
The inﬂuenza subunit vaccine and the GEM particles were
admixed just before the immunization. The test group was
immunized intranasally with 12 µl of GEM adjuvanted
vaccine (2.5×10
9 GEM particles (1 U) were mixed with
12 µl of 5 µg HA) divided over both the nostrils under
inhalation anesthesia (isoﬂurane/O2). In two control groups,
one group was injected with an intramuscular injection of
50 μl vaccine in posterior thigh muscles under inhalation
anaesthesia (isoﬂurane/O2) and second group was
administered 12 µl of vaccine intranasally under inhalation
anaesthesia (isoﬂurane/O2). The mice were sacriﬁced 2 weeks
after the second booster vaccination, i.e., on day 42. After the
animals were sacriﬁced, the spleens of the animals were
harvested and subsequently stored in supplemented Iscoves’s
modiﬁed Dulbecco’s medium–glutamax medium with 5%
fetal calf serum, 1% penicillin/streptomycin, and 50 μM β-
mercaptoethanol at 4°C.
Sera Collection and Mucosal Washes
Blood samples were drawn three times during the
experiments, i.e., on day 0 and 28 by orbital puncture and
day 42 by heart puncture. Sera were obtained by centrifuga-
tion of blood at 1,200×g for 5 min, and the samples were
subsequently stored at −20°C until further analysis.
Nasal and lung lavages were performed as described
earlier (34). Brieﬂy, the trachea of each mouse was cannulated
and connected to a 1-ml syringe. Lung washes were taken by
repeated ﬂushing of lungs with 1 ml PBS (pH 7). Nasal washes
were obtained by ﬂushing the nasopharynx with 1 ml PBS.
Subsequently, the mucosal washes were admixed with 10 µl of
protease inhibitor solution (one tablet Complete® protease
inhibitor cocktail (Roche diagnostics) dissolved in 2 ml PBS).
ELISA
The antibody response to the inﬂuenza subunit antigen
was determined using enzyme-linked immunosorbent assays
as described previously (34). Brieﬂy, the plates were incu-
bated with 200 ng of HA/well. After overnight incubation
with HA, the plates were blocked with 3% bovine serum
albumin (BSA; Sigma-Aldrich, The Netherlands). Then,
plates were washed and incubated with sera and mucosal
samples in serial dilution for 1.5 h at 37°C. Next, the plates
were washed and incubated with horseradish peroxidase-
conjugated goat antibodies directed against mouse IgG, IgG1,
IgG2a, IgG2b, and IgA (Southern Biotech, Birmingham, AL,
USA). Finally, the substrate solution (0.02% 1,2-phenyllendi-
amine dihydrochloride in 50 mM phosphate buffer pH 5.6,
containing 0.006% H2O2) was added and the plates were
incubated in the dark for 30 min at room temperature. The
reaction was stopped by addition of 2 M H2SO4,a n d
absorbance at 490 nm was read with a Benchmark Microplate
reader (BioRad, Hercules, CA, USA). Titers reported are the
110 Saluja et al.reciprocal of the calculated sample dilution corresponding
with an A490≥0.2 after background correction.
Hemagglutination Inhibition Assay
Hemagglutination inhibition (HI) titers in serum were
determined as described previously (34). Brieﬂy, serum was
inactivated at 56°C for 30 min. In order to reduce nonspeciﬁc
hemagglutination, 25% kaolin suspension was added to
inactivated sera. After centrifugation at 1,200×g, 50 µl of the
supernatant was transferred in duplicate to 96-well round-
bottom plate (Greiner, Alphen a/d Rijn, The Netherlands)
and serially diluted twofold in PBS. Then, four hemaggluti-
nation units of A/Wisconsin inﬂuenza inactivated virus were
added to each well, and the plates were incubated for 40 min
at room temperature. Finally, 50 µl of 1% guinea pig red
blood cells was added to each well and incubated for 2 h at
room temperature. The highest dilution capable of preventing
hemagglutination was scored as HI titer.
ELISPOT
The Elispot assay was performed as described earlier
(35). Brieﬂy, 96-well microtiter plates (Greiner, Alphen a/d
Rijn, The Netherlands) were incubated overnight at 4°C with
antimouse interferon-γ (IFN-γ) and interleukin-4 (IL-4; BD,
Pharmingen, Erembodegem, Belgium). After washing the
plates three times with PBS/Tween (Sigma-Aldrich, The
Netherlands), they were blocked (PBS + 4% BSA) for 1 h
at 37°C, and spleen cells were added to the plates in con-
centration 1×10
6cells/well with or without subunit vaccine as
a stimulation peptide. After incubation overnight at 37°C, 5%
CO2, the cells were lysed with cold water. Next, the plates
were washed ﬁve times with PBS/Tween and incubated with
biotinylated antimouse IFN-γ and IL-4 antibodies (BD
Pharmingen) in concentration of 0.125 µg/ml in PBS + 2%
BSA. After washing, the plates were incubated with
streptavidin alkaline phosphatase (BD Pharmingen) for 1 h
at 37°C. Finally, after washing three times with PBS/Tween
and two times with PBS, the spots were developed using the
substrate solution consisting of 1 mg/ml 5-bromo-4-chloro-3-
indolylphosphate, 0.92% (w/v) 2-amino-2-methyl-1-propanol,
0.08 µl/ml TritonX-405, 1 M MgCl2, and 6 mg/ml agarose. The
spots were counted using an Elispot reader (A.EL.VIS
Elispot reader).
Statistical Analysis
Statistical analyses were performed using Student’s t test
with p<0.05 as the minimal level of signiﬁcance. The results




The protective capacity of inﬂuenza vaccines was deter-
mined by measuring HI titers. The HI titers were determined
for all mice after the ﬁrst and second booster immunization.
Figure 1 shows that both the conventional i.m. and the GEM
adjuvanted i.n. vaccines reached comparable HI titers above
2log6 after the ﬁrst booster immunization (p=0.2062). These
titers increase in both cases to values between
2log7 and
2log8
with no signiﬁcant differences (p=0.7611). I.n. immunization
with the subunit vaccine alone induced low HI titers, even
after two booster immunizations. Moreover, only 50% of the
animals responded after immunization with i.n. subunit
vaccine, while all animals responded in the two other
vaccine groups. Since an HI titer above
2log5 is considered
to be protective in humans, these results indicate that one
single boost is sufﬁcient for i.n. GEM adjuvanted inﬂuenza
vaccines to reach protective immunity.
As expected,i.m. immunization withconventional subunit
vaccine resulted in robust IgG responses while this vaccine
without adjuvant was poorly immunogenic when administered
via the i.n. route (26,36–38). Figure 2 shows the subunit
antigen-speciﬁc IgG response after two booster doses. Even
after two booster doses, i.n. immunization with subunit vaccine
alone induced lower (p<0.01) IgG responses than i.n admin-
istered HA + GEM, clearly demonstrating the adjuvant effect
of the GEM particles. While the i.m. immunization with
conventional subunit vaccine resulted in a higher response
(p=0.0101) than i.n. immunization with HA + GEM after
the ﬁrst booster dose, the IgG response was comparable (p=
0.4355) after the second booster immunization. This is
Fig. 1. Subunit antigen-speciﬁc HI titers in mice immunized three
times. a Comparative analysis of HI titers in different groups, i.e.,
i.m., i.n., and i.n. + GEM at 0, 28, and 42 days after the ﬁrst
immunization. b Comparative analysis of HI titers between three
groups, i.e., i.m., i.n., and i.n. + GEM at 42 days after ﬁrst
immunization. The numbers above the columns indicate the
number of responders per group
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thatduringi.n.immunization,thereisagradualincreaseinIgG
response.
Furthermore, i.n. immunization without adjuvant and i.m
immunization induced low levels of serum IgA titers (Fig. 3).
Moreover, only three out of eight and ﬁve out of eight
animals responded after i.n. and i.m. immunization with
subunit vaccine, respectively. In contrast, i.n. immunization
with HA + GEM induced higher (p<0.05) serum IgA
responses than the other two control immunizations, and all
animals responded in this group. It is evident from the results
that formulation of subunit vaccine with GEM particles
induced a strong systemic immune response compared to
both i.n. and i.m. immunization with subunit vaccine alone.
Mucosal Immune Response
It has been reported previously that i.n. immunization
may induce local mucosal immunity in the respiratory tract,
i.e., the port of entry of inﬂuenza virus (36,38–40). The
activation of the mucosal immunity primes the underlying B
and T cells and results in secretion of sIgA at mucosal sites.
Consequently, the inﬂuenza speciﬁc sIgA titers were deter-
mined in nasal and lung lavages of the mice (Fig. 4).
I.m. immunizations elicited sIgA levels in nasal and lung
lavages below detection limits in most of the mice (only one
out of eight mice showed a response in the nasal lavage).
Similarly, the i.n. immunizations with subunit vaccine alone
gave low sIgA titers in lung and nasal lavages (three out of
eight responders). In contrast, i.n. immunization with HA +
GEM induced high sIgA titers in nasal and lung lavages of all
mice. In conclusion, i.n. immunization with HA + GEM
induced a strong mucosal immune response at both the upper
and lower respiratory tract.
Fig. 2. Subunit antigen-speciﬁc total serum IgG titers in mice
immunized three times. a Comparative analysis of total serum IgG
titers in different groups, i.e., i.m., i.n., and i.n. + GEM at 0, 28, and
42 days after the ﬁrst immunization. b Comparative analysis of total
serum IgG titers between three groups, i.e., i.m., i.n., and i.n. + GEM
at 42 days after ﬁrst immunization. **p<0.01
Fig. 3. Subunit antigen-speciﬁc total serum IgA titers in mice
immunized i.m., i.n., and i.n. + GEM. The numbers above the columns
indicate the number of responders per group
Fig. 4. Subunit antigen-speciﬁc sIgA titers in nasal (a) and lung
lavages (b) of mice immunized i.m., i.n., and i.n. + GEM. The numbers
above the columns indicate the number of responders per group
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In order to evaluate the phenotype of the response, i.e.,
the T-helper 1/T-helper 2 ratio (Th1/Th2), IgG subtypes, and
IFN-γ and IL-4 responses were determined. IgG subtype
proﬁling (Fig. 5) showed that i.n. immunization with subunit
vaccine alone induced low IgG1, IgG2a, and IgG2b
responses. As previously reported (34,35), i.m. immunization
with subunit vaccine induced high IgG1 responses but little
IgG2a and IgG2b, indicating an immune response biased
toward a Th2-type response. In comparison to i.m. immuni-
zation, i.n. immunization with HA + GEM induced signiﬁcant
higher IgG2a (p=0.042) and IgG2b (p=0.030) and lower
IgG1 (p=0.0135) responses. These results indicate that the
antibody responses generated by i.n. HA + GEM vaccine is
signiﬁcantly more skewed toward a Th1 phenotype than the
conventional i.m. vaccine.
The type of immune response (Fig. 6) was further
evaluated by determining antigen-speciﬁc IFN-γ- and IL-4-
producing splenocytes of the immunized mice. I.m. immuni-
zation with subunit vaccine resulted in a higher number of
IL-4-producing cells than IFN-γ-producing cells, indicating
again a predominated Th2-type response. I.n. immunization
with subunit vaccine resulted in lower numbers of IL-4-
producing cells but substantially higher numbers of IFN-γ-
producing cells (Fig. 6), resulting in a balanced Th1/Th2
response. The increase in IFN-γ-producing T cells was even
signiﬁcantly (p=0.0373) more pronounced after i.n. immuni-
zation with HA + GEM, indicating a shift of the immune
response from a balanced Th1/Th2 to a predominant Th1-
type response. Collectively, these results indicate that the
GEM-based i.n. inﬂuenza vaccine elicited a response biased
toward a Th1 phenotype.
DISCUSSION
In this study, we demonstrated that GEM particles are
promising candidates as an adjuvant for the i.n. delivery of
the inﬂuenza subunit vaccine. Our results show that intra-
nasally administered subunit vaccine adjuvanted with GEM
particles (which are simply mixed with vaccine) can be used
in a prime-boost vaccination strategy to induce protective
levels of HI titers (>
2log5 (41)), which is considered to be an
important correlate of protection. In addition, the serum IgG
Fig. 5. Subunit antigen-speciﬁc serum IgG subtype titers in sera of
mice immunized i.m., i.n., and i.n. + GEM. The IgG1 (a), IgG2a (b),
and IgG2b (c) titers were determined. *p<0.05
Fig. 6. The type of the immune response was determined by the
cytokine release proﬁle, i.e., IL-4 (a) and IFN-γ (b) in mice immunized
i.m., i.n., and i.n. + GEM. *p<0.05
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immunogenicity of the i.n. administered inﬂuenza subunit
vaccine.
In addition to substantial serum responses, the GEM
adjuvanted i.n. vaccine elicited a strong mucosal immune
response, i.e., secretion of the sIgA in the respiratory mucosa.
These results are consistent with earlier studies (31) in which
GEM bound pneumococcal i.n. vaccine induced strong
mucosal responses. Induction of signiﬁcant levels of sIgA in
nasal mucosa shows that GEM particles act as immuno-
potentiators in the nasal mucosa. The immune system of the
nasal mucosa consists of the nasal-associated lymphoid tissue
(NALT). In the NALT, the antigens are taken up by the M-
cells and then presented to antigen-presenting cells, which in
turn present antigen fragments to the underlying B and Tcells
(6,13,42,43). This cascade of events is required for the initial
innate and adaptive immune response against the inﬂuenza
virus. The induction of sIgA antibodies in the NALT might be
the result of an interaction with Toll-like receptor (TLR)-2 of
the peptidoglycan present in GEM particles, as it is known that
GEM particles act as a TLR-2 agonist in in vitro studies
(Pasetti et al., manuscript in communication). Furthermore, it
is known that GEM particles can activate the maturation of the
dendritic cells and macrophages in vitro (32). Thus, both the
activation of TLR-2 and maturation of the dendritic cells might
have contributed to the stronger mucosal immune response.
Recently, much emphasis is put on the phenotype of the
immune response, i.e., Th1, Th2, or balanced response (44–46).
ATh1 response is considered to be superior to Th2 or a mixed
response (47) because it (1) results in better protection from
infection (16) and (2) helps in virus neutralization by secretion
of INF-γ (48). Moreover, the natural infection also induces a
Th1 type of response. However, subunit vaccine administered
via the i.n. route and many of the nasal adjuvants like chitosan
(36,49), ISCOMS (50), lipids (24,51), and LT (25) induce a
mixed Th1/Th2-type response. In contrast, the i.n. GEM
inﬂuenza vaccine induced a response skewed toward Th1 type.
Thus,GEMparticles modulate theresponse from abalancedto
a Th1-skewed response.
Furthermore, the vaccine formulation presented in this
paper is much more convenient to produce compared to most
of the other adjuvant systems which have to be preformulated
(24,36,39,49–52). The formulation used in these experiments
was prepared by ad-mixing the GEM particles with conven-
tional subunit vaccine. GEM particles can be produced in
large quantities under sterile conditions and can be stored at
ambient temperature for long time (29). The ease of
formulation and administration makes i.n. GEM inﬂuenza
subunit vaccine a promising candidate for vaccination in a
pandemic as well as in an epidemic situation.
Amajorhurdleinthedevelopmentofmucosaladjuvantsis
to proof their safety in order to obtain approval by regulatory
agencies.TheGEMparticlesusedinthisstudyaresafetousein
comparison to other adjuvants and other lactic acid bacteria
systems evaluated for vaccination (27,53,54). During the
production of GEM particles, L. lactis bacteria are treated with
acid, which results in loss of genetic material. The loss of the
genetic material is beneﬁcial as the problem of DNA shedding
and infection in the mucosal layer by the bacteria is avoided
(30). Moreover, the GEM particles are produced from a
bacterium which is used in the production of dairy products
and is considered a GRAS organism. Audouy et al. (31)
reported that GEMs did not induce detectable antibody
levels to particles themselves after repeated intranasal
administrations in mice. In addition, GEM particles have
already been tested intranasally in rabbits in a preclinical
GLP toxicity study, and no adverse events were reported
(Leenhouts et al., unpublished results). Therefore, GEM
particles can be considered as a safe candidate adjuvant for
mucosal use in humans.
CONCLUSION
Our data show that i.n. inﬂuenza vaccine adjuvanted
with GEM particles induced a comparable systemic immunity
and superior mucosal and cell-mediated immunity compared
to i.m. immunization with subunit inﬂuenza vaccine alone.
Importantly, it induced higher sIgA levels which are a ﬁrst
line of defense during inﬂuenza infection in the upper
respiratory tract. Moreover, it elicited a skewed Th1-type
immune response which is considered to provide superior
protection. Overall, GEM particles can be regarded as a safe
and potent adjuvants for i.n. delivered inﬂuenza subunit
vaccine.
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